Preliminary Imaging Results Using In-111 Labeled CYT-356 (Prostascintst) in the Detection of Recurrent Prostate Cancer

Sodee, D. Bruce; Conant, Ridgely; Chalfant, M; Miron, Stefan D.; Klein, Eric A.; Bahnson, Robert R.; Spirnak, J. Patrick; Carlin, Bruce I.; Bellon, Errol M.; Rogers, Barbara

doi:10.1097/00003072-199610000-00002

Cited by 57 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior investigations have demonstrated that 111 In-capromab pendetide immunoscintigraphy is safe, with mild adverse effects and minimally elevated human antimouse antibody levels on rare occasion. 18,19 PSMA is a 100-kD transmembrane glycoprotein produced by both benign and malignant prostate epithelial cells. PSMA is expressed more abundantly in malignant prostate tissue compared with normal or hypertrophic prostate tissue and in poorly differentiated tumors compared with well-differentiated tumors.…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

Raj

Partin

Polascik

2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDDespite the ability of radical prostatectomy to eradicate prostate carcinoma, biochemical evidence of recurrent prostate carcinoma may be seen in approximately 40% of patients 15 years after they undergo surgery. Localization of recurrent disease after radical prostatectomy is difficult and may greatly influence subsequent clinical management. The authors examined the utility of indium 111 (111In)‐capromab pendetide immunoscintigraphy to detect recurrent prostate carcinoma radiographically in men with early biochemical evidence of failure (serum prostate specific antigen [PSA] ≤ 4.0 ng/mL) and assessed the minimum serum PSA level necessary for imaging recurrent disease.METHODSBetween May 1987 and August 1995, 255 hormone‐naïve men with a mean (± standard deviation) age of 65 years ± 7 years who underwent radical prostatectomy for clinically localized prostate carcinoma were followed without adjuvant therapy until early PSA recurrence in this multicenter study. Preoperatively, all patients had negative bone scans and pathologically negative lymph nodes, and they did not undergo hormonal ablation, chemotherapy, or radiation therapy preoperatively or postoperatively until the 111In‐capromab pendetide scan was performed. All men in this study had postoperative serum PSA levels ≤ 4.0 ng/mL at the time of radionuclide imaging. All men underwent imaging with the capromab pendetide scan to localize recurrent disease, and charts were reviewed to document clinical evidence of recurrence.RESULTSPathologic findings included mean Gleason scores of 6.7 ± 1.2; pathologic tumors classified as pT2a (18%), pT2b (26%), pT3a (38%), pT3b (16%), and pT4a (2%); a pathologic lymph node status of pN0 (100%); positive surgical margins (44%); and perineural invasion (42%). Capromab pendetide uptake was seen in 72% of 255 men throughout a range of patients' postoperative serum PSA levels (0.1–4.0 ng/mL), with 31% of men having local uptake (prostatic fossa) only. Of 151 men who underwent additional imaging studies, 16 of 139 men (12%) and 15 of 92 men (16%) showed evidence of recurrent disease by bone scintigraphy and computed tomography scans, respectively. Gleason score, pathologic stage, perineural invasion, and margin status were not correlated significantly with the 111In‐capromab pendetide scan.CONCLUSIONSCapromab pendetide imaging can localize early PSA recurrence and may guide appropriate treatment after patients undergo radical prostatectomy. No minimum serum PSA value was needed to potentially detect radiographic disease after surgery. Further confirmatory studies and long‐term follow‐up of this cohort documenting response to salvage therapy are needed to validate these imaging findings. Cancer 2002;94:987–96. © 2002 American Cancer Society.DOI 10.1002/cncr.10337

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

Raj

Partin

Polascik

2002

Cancer

View full text Add to dashboard Cite

show abstract

“…It also affects neighboring cells with a heterogeneous antigen expression or insufficient vascularization, which is so called "bystander effect" (Rzeszowska-Wolny et al, 2009). An initial immunoscintigraphic approach targeting PSMA was done with the 111 Indium ( 111 In) labeled anti-PSMA monoclonal antibody 7E11 (Capromab Pendetide (Prosta Scint®), Cytogen, Philadelphia, PA) (Kahn et al, 1994;Sodee et al, 1996;Kahn et al, 1998). With this radioimmunoconjugate a higher sensitivity was reached in the imaging of prostate cancer soft tissue metastases compared to Computed Tomography (CT) or Magnetic Resonance Tomography (MRT) .…”

Section: Anti-psma Radioimmunotherapymentioning

confidence: 99%

Prostate Specific Membrane Antigen as Biomarker and Therapeutic Target for Prostate Cancer

Wolf¹

2011

Prostate Cancer - Diagnostic and Therapeutic Advances

View full text Add to dashboard Cite

“…Figure 3 shows patients free of biological recurrence, with PSA greater than 0.3 and 1.0 ng/ml. Four patients developed a PSA 44.0 ng/ ml, one had a negative biopsy, bone scan, pelvis MRI, Prostacinct study 19 (In-111 labeled Copramab Pendetide, Cytogen Corp., Princeton, NJ, USA) and has had no other treatment. Three patients began hormone treatment on the basis of a rapidly rising PSA: one had two sets of TRUS-guided biopsies that were negative for any cancer or viable residual prostate tissue.…”

Section: Participant Characteristicsmentioning

confidence: 99%

Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy

Donnelly

Saliken

Ernst

et al. 2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Despite improvements in treatment of localized prostate cancer, local recurrence remains a significant problem. A total of 46 patients with proven local cancer recurrence following external beam radiotherapy entered a prospective clinical trial using ultrasound-guided cryosurgery to ablate the residual prostate gland. Persistent complications included one urethra-rectal fistula, incontinence (2), retention (3), and treatment induced erectile dysfunction (7). Using the PSA definitions for biochemical failure as PSA X0.3 ng/ml, the Kaplan-Meier plots showed the incidence of patients to be free of biochemical recurrence at 51 and 44% at 1 and 2 y, respectively. For a PSA X1.0, the values at 1 and 2 y were 72 and 58%.

show abstract

Preliminary Imaging Results Using In-111 Labeled CYT-356 (Prostascintst) in the Detection of Recurrent Prostate Cancer

Cited by 57 publications

References 16 publications

Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

Prostate Specific Membrane Antigen as Biomarker and Therapeutic Target for Prostate Cancer

Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy

Contact Info

Product

Resources

About